US regulatory advisors are not recommending approval of Johnson & Johnson’s Plivensia for rheumatoid arthritis, having concluded – based on the data available – that the benefits of the drug do not outweigh the potential risks.
Read More
GlaxoSmithKline has filed for approval of a subcutaneous formulation of its lupus drug Benlysta on both sides of the Atlantic.
Read More
GlaxoSmithKline has filed an application in Europe seeking approval to market its investigational human anti-interleukin (IL)-6 monoclonal antibody sirukumab for the treatment of rheumatoid arthritis (RA).
Read More
